-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WgjcEzFyDPrXWeJvh+mkZsHOARf5vKaIUrsD9+/GffwdqdvLskgIcc/d8MgAzIZx
 3QBMD+k/aw6NS8hmLqMSHw==

<SEC-DOCUMENT>0001075880-04-000043.txt : 20041122
<SEC-HEADER>0001075880-04-000043.hdr.sgml : 20041122
<ACCEPTANCE-DATETIME>20041122080008
ACCESSION NUMBER:		0001075880-04-000043
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041122
FILED AS OF DATE:		20041122
DATE AS OF CHANGE:		20041122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		041159293

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc04110411.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2004

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 22 November,2004  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
4 NOVEMBER 2004

ASX & MEDIA RELEASE
22 NOVEMBER 2004

RESEARCHERS REPORT THAT ORAL PHENOXODIOL SLOWS DISEASE
PROGRESSION IN LATE-STAGE PROSTATE CANCER PATIENTS

Novogen Limited's subsidiary, Marshall Edwards, Inc.
(LSE AIM: MSH and Nasdaq: MSHL) has just made the
following announcement to the London Stock Exchange's
Alternative Investment Market.

(WASHINGTON, DC  - November 22, 2004) Marshall Edwards,
Inc., today released the final results of a small-scale
clinical study of the investigational anti-cancer drug,
phenoxodiol, in patients with hormone-refractory prostate
cancer (HRPC).  The results, presented on the evening of
November 19 to the American Association of Cancer Research
(AACR) conference on Basic, Translational and Clinical
Advances in Prostate Cancer, held in Bonita Springs,
Florida, showed that phenoxodiol has a potent ability
to slow down the rate of cancer progression as evidenced
by PSA levels and clinical status.

Phenoxodiol (oral dosage formulation) is being developed
as a treatment for HRPC, both as a first-line chemotherapy,
and as a second-line chemotherapy for patients who have failed
to respond to docetaxel.

Phenoxodiol is an investigational drug and has not been
approved for marketing by FDA.  Under U.S. law, a new drug
cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for
the intended use.

About the study

The Phase Ib/IIa clinical study was conducted in two Australian
hospitals.  Nineteen men with HRPC were treated with phenoxodiol
daily for 3 weeks each month for 6 months.  All men had advanced,
metastatic disease, and entered the trial with rising PSA levels.
The primary objectives of the study were to examine
(a) the safety and tolerability of phenoxodiol in men with HRPC,
(b) the ability to maintain a steady-state of phenoxodiol
in the blood, and
(c) the effect of phenoxodiol on PSA levels and disease progression.
The main purpose of the study was to provide evidence of a clinical
benefit that would justify conducting a large-scale study to
determine the ability of phenoxodiol to reduce tumor progression.
Another purpose was to determine an appropriate dosage of
phenoxodiol to be used in such a study.

Patients received one of four different dosages of
phenoxodiol - 20, 80, 200 or 400 mg each 8 hours.
There were between 4 and 6 patients per dose stratum.  Treatment
continued for 6 months or until disease progression.  Patients
who were considered to have derived a clinical benefit from
phenoxodiol after 6 months of therapy were continued on 200 mg
phenoxodiol until disease progression.

About the results

Phenoxodiol produced a dose-response effect in terms of disease
progression and PSA levels, with the 20 mg dose producing no
discernible effect, the 80 mg dose an intermediate effect, and
the 200 and 400 mg doses producing a marked effect.

The clinical effect of phenoxodiol was measured in two standard
ways
(i) the proportion of patients at 6 months who had shown disease
progression (determined on the basis of time to PSA levels being
greater than 25% higher than base-line and/or on the basis of
clinical determination), and
(ii) PSA response (greater than 50% fall in PSA level compared
to base-line for at least 4 weeks' duration).

Increasing doses of phenoxodiol resulted in a progressive and
marked increase in the time taken for the disease to progress.
In the 20 and 80 mg dose groups, all patients had shown disease
progression by the end of the study, with average times to
progression of 10 and 17 weeks, respectively.
However, in the 200 and 400 mg dose groups, 2 of 4 and 3 of 4
patients respectively had no evidence of disease progression
at 6 months.  The PSA levels in these 5 patients without disease
progression at 6 months were at or below baseline levels.

A PSA response generally is regarded as indicative of tumor
response.  Two of four patients in the 200 mg dose group,
and 3 of 4 patients in the 400 mg dose group showed a PSA
response, which taken together with the disease progression
data suggests that phenoxodiol monotherapy is exerting a
significant anti-tumor effect in these late-stage,
hormone-refractory cancers.

Phenoxodiol was well tolerated in all patients, with no
toxicities being reported, including at dosages of 400 mg
administered for 6 months, followed by 200 mg for up to a
further 18 months.

The 8-hourly dosing schedule also proved effective at providing
steady-state plasma levels of phenoxodiol with no long-term
accumulation of drug at any of the four dosages.

Professor Graham Kelly PhD, Chairman, Marshall Edwards, Inc.,
who presented the data at the conference on behalf of the
investigators, said, "These results give us optimism that
with phenoxodiol we can slow the rate of tumor progression
to the point where we can make a real difference to the survival
of men with such advanced cancer. Current therapies offer
only modest extensions of life to about half of patients with
HRPC, but at the cost of significant toxicity to most men
receiving the treatment.  Our aim with phenoxodiol is to
deliver meaningful prolongation of life in a significant
number of patients, with little or no toxicity."

A Phase IIb/IIIa multi-center, international, clinical trial
known as the COMPACT (Comparison of Phenoxodiol
Against Conventional Therapy) Study in men with HRPC using
a phenoxodiol dosage of 400 mg currently is being established.

About prostate cancer

Prostate cancer is one of the most common types of cancer
among American men.  According to the American Cancer
Society, over 230,000 American men will be diagnosed with
prostate cancer in 2004, and approximately 29,900 American
men will die from the disease.
Prostate cancer is strongly associated with the male sex
hormone, testosterone, and most early cases of prostate cancer
respond for some time to hormonal therapy that blocks the ability
of testosterone to stimulate the cancer.  However, the majority
of cases of prostate cancer eventually become independent of
testosterone, at which time they are known as hormone-refractory
prostate cancer (HRPC).  The cancer at this stage typically is
metastatic, with a patient survival time typically in the range
of 1 to 2 years.

The FDA recently approved the combination of docetaxel (Taxotere)
and prednisone for the treatment of HRPC.  That combination produces
a PSA response in 45% of patients, although the tumor response rate
is only 12% and the overall increase in survival in all patients
is 10 weeks (from an average of 16.4 months to an average of
18.9 months).(see references 1 and 2 quoted below).


About phenoxodiol

Phenoxodiol is an investigational product designed to block
the key pro-survival signaling messenger,
sphingosine-1-phosphate.  As a consequence of this,
the prostate cancer cell is both blocked from dividing
or increasing in number (cytostasis) and induced to undergo
apoptosis or programmed cell-death (cytotoxicity).
Phenoxodiol is believed to target the cell membrane enzyme,
tNADH oxidase, which regulates the production of
sphingosine-1-phosphate.  The restriction of tNADH oxidase to
cancer cells accounts for the highly selective effect of
phenoxodiol on cancer cells.

About Marshall Edwards, Inc.

Phenoxodiol, an isoflavonoid ring structure, is being developed
by Marshall Edwards, Inc.,  (Nasdaq: MSHL - LSE AIM:MSH)
which has licensed rights to bring phenoxodiol to market
globally from Novogen Limited, an Australian biotechnology
company based in Sydney, Australia (Nasdaq: NVGN - ASX: NRT).

More information on phenoxodiol and on Marshall Edwards can be
found at www.marshalledwardsinc.com.

References.
1. Tannock IF, et al. (2004) New Eng J Med 351, 1502-1512.
2. Petrylak DP, et al. (2004) New Eng J Med 351, 1513-1520.



Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
